Mark Lamotte

2.3k total citations
127 papers, 1.6k citations indexed

About

Mark Lamotte is a scholar working on Endocrinology, Diabetes and Metabolism, Economics and Econometrics and Surgery. According to data from OpenAlex, Mark Lamotte has authored 127 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Endocrinology, Diabetes and Metabolism, 34 papers in Economics and Econometrics and 28 papers in Surgery. Recurrent topics in Mark Lamotte's work include Diabetes Treatment and Management (33 papers), Health Systems, Economic Evaluations, Quality of Life (32 papers) and Diabetes Management and Research (21 papers). Mark Lamotte is often cited by papers focused on Diabetes Treatment and Management (33 papers), Health Systems, Economic Evaluations, Quality of Life (32 papers) and Diabetes Management and Research (21 papers). Mark Lamotte collaborates with scholars based in United Kingdom, Belgium and United States. Mark Lamotte's co-authors include Lieven Annemans, V. Foos, Phil McEwan, David Grant, James L. Palmer, Adam Lloyd, Laetitia Gerlier, K Moeremans, A Uyttebroeck and Han Myint and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Mark Lamotte

120 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Lamotte United Kingdom 22 564 306 279 265 243 127 1.6k
Per Ivarsen Denmark 24 324 0.6× 366 1.2× 255 0.9× 140 0.5× 309 1.3× 87 1.8k
Chris Colby United States 12 213 0.4× 143 0.5× 350 1.3× 112 0.4× 343 1.4× 26 1.2k
Natalie Staplin United Kingdom 20 417 0.7× 460 1.5× 258 0.9× 84 0.3× 248 1.0× 57 1.4k
Melissa C. Caughey United States 27 244 0.4× 1.1k 3.4× 314 1.1× 97 0.4× 252 1.0× 116 2.3k
Seongjun Ha South Korea 6 277 0.5× 364 1.2× 308 1.1× 55 0.2× 187 0.8× 8 1.8k
David C. Wheeler United Kingdom 18 234 0.4× 299 1.0× 263 0.9× 182 0.7× 178 0.7× 40 1.5k
Anita Lloyd Canada 16 266 0.5× 375 1.2× 314 1.1× 109 0.4× 191 0.8× 37 1.4k
Rachel Middleton United Kingdom 22 249 0.4× 381 1.2× 233 0.8× 106 0.4× 326 1.3× 47 1.9k
Thaminda Liyanage Australia 8 219 0.4× 211 0.7× 321 1.2× 173 0.7× 212 0.9× 12 2.1k
Geetha Maddukuri United States 11 272 0.5× 155 0.5× 246 0.9× 58 0.2× 200 0.8× 14 1.5k

Countries citing papers authored by Mark Lamotte

Since Specialization
Citations

This map shows the geographic impact of Mark Lamotte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lamotte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lamotte more than expected).

Fields of papers citing papers by Mark Lamotte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lamotte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lamotte. The network helps show where Mark Lamotte may publish in the future.

Co-authorship network of co-authors of Mark Lamotte

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lamotte. A scholar is included among the top collaborators of Mark Lamotte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lamotte. Mark Lamotte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Larsen, Sára, et al.. (2024). Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective. International Journal of Obesity. 48(5). 683–693. 10 indexed citations
2.
Holst‐Hansen, Thomas, et al.. (2024). The Correlation Between Body Mass Index and Health-Related Quality of Life: Data from Two Weight Loss Intervention Studies. Advances in Therapy. 41(11). 4228–4247. 1 indexed citations
3.
Gerlier, Laetitia, et al.. (2023). CKD Progression Model (CKD-PM): Development and Validation. Journal of the American Society of Nephrology. 34(11S). 666–666. 2 indexed citations
4.
5.
Ehlers, Lars Holger, et al.. (2021). The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease. Diabetes Therapy. 12(5). 1523–1534. 15 indexed citations
6.
Foos, V., et al.. (2018). PDB116 - THE RELATIONSHIP BETWEEN POOR ADHERENCE AND HBA1C AND WEIGHT CHANGES IN PATIENTS WITH TYPE 2 DIABETES. Value in Health. 21. S138–S138. 1 indexed citations
7.
Foos, V., Phil McEwan, & Mark Lamotte. (2016). Implications of Introducing Patient Heterogeneity in Cost Effectiveness Modeling. Value in Health. 19(7). A371–A371. 1 indexed citations
8.
Lamotte, Mark, et al.. (2016). Economic Evaluation of Ipilimumab in First Line Treatment of Advanced Melanoma in Italy. Global & Regional Health Technology Assessment. 3(2). GRHTA.5000230–GRHTA.5000230. 2 indexed citations
9.
10.
Gerlier, Laetitia, Mark Lamotte, & Philippe Chévalier. (2015). Assessing The Burden of Systemic Lupus Erythematosus In Belgium Using A Longitudinal Hospital Database. Value in Health. 18(7). A667–A667. 1 indexed citations
11.
Lamotte, Mark, et al.. (2014). Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in Belgium. Value in Health. 17(3). A248–A248. 1 indexed citations
12.
McEwan, Phil, et al.. (2013). Drivers Of Cost-Effectiveness In Type-2 Diabetes Mellitus. Value in Health. 16(3). A165–A165.
13.
14.
Lamotte, Mark, et al.. (2013). The Burden Of Hospitalizations Due To Insulin Related Hypoglycemia In Belgium. Value in Health. 16(3). A161–A161. 1 indexed citations
15.
Foos, V., James L. Palmer, David Grant, et al.. (2012). PRM58 Long-Term Validation of the IMS CORE Diabetes Model in Type 1 and Type 2 Diabetes. Value in Health. 15(7). A470–A470. 10 indexed citations
16.
Spaepen, Erik, Mark Lamotte, E. Walter, et al.. (2011). PSY10 COST ANALYSIS OF ANEMIA TREATMENT WITH ERYTHROPOIESES-STIMULATING AGENTS (ESAS) IN CANCER PATIENTS RECEIVING CHEMOTHERAPY: A MULTICOUNTRY APPROACH. Value in Health. 14(3). A60–A60. 2 indexed citations
17.
Nikkels, Arjen, et al.. (2009). Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes.. PubMed. 8(11). 992–6. 8 indexed citations
18.
Lamotte, Mark, Lieven Annemans, D. Michielsen, et al.. (2005). [The cost of complicated acute urinary retention: a patient chart analysis in Belgium].. PubMed. 60(11). 875–81. 3 indexed citations
19.
Roze, S, et al.. (2004). Coste-efectividad de irbesartan en pacientes hipertensos con nefropatía diabética tipo II: una perspectiva española. Nefrología. 24(3). 231–238. 3 indexed citations
20.
Palmer, Andrew, Lieven Annemans, S Roze, et al.. (2004). [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].. PubMed. 24(3). 231–8. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Per Ivarsen Breakdown of academic impact, for papers by Chris Colby Breakdown of academic impact, for papers by Natalie Staplin Breakdown of academic impact, for papers by Melissa C. Caughey Breakdown of academic impact, for papers by Seongjun Ha Breakdown of academic impact, for papers by David C. Wheeler Breakdown of academic impact, for papers by Anita Lloyd Breakdown of academic impact, for papers by Rachel Middleton Breakdown of academic impact, for papers by Thaminda Liyanage Breakdown of academic impact, for papers by Geetha Maddukuri
Rankless by CCL
2026